Abstract |
INJECTABLE SPECTROGRAMIN: Combination regimens using quinupristin/dafopristin with either gentamicin or vancomycin have powerful bactericidal activities (even against quinupristin-resistant strains) against methicillin-resistant Staphylococcus aureus (MRSA) in a model of experimental endocarditis in the rabbit. In clinical trials, quinupristin/dalfopristin is becoming a therapeutic alternative to consider after failure of conventional antistaphylococcal treatments. NEW GENERATION CEPHALOSPORINS: These new cephalosporins, particularly C-3 pyridinium-thiomethyl- cephalosporins, new (3-dithiocarbamoyl) cephalosporins, and a series of new compounds with high affinity for MRSA PLP2a, are particularly active against MRSA and are unaffected by beta-lactamases. A NEW CARBAPENEM: This new antibiotic has a wide bactericidal effect against Gram-positive organisms and is active against MRSA as well as penicillin-resistant S. pneumoniae. NEW FLUOROQUINOLONE DERIVATIVES: In vitro, these new derivatives have been found to be active against MRSA, pneumococci non-sensitive to ciprofloxacin, and Bacteroides fragilis, Mycobacterium tuberculosis, Chlamydia pneumoniae.
|
Authors | E Bergogne-Bérézin |
Journal | Presse medicale (Paris, France : 1983)
(Presse Med)
Vol. 29
Issue 37
Pg. 2023-7
(Dec 02 2000)
ISSN: 0755-4982 [Print] France |
Vernacular Title | Résistances et nouvelles stratégies antibiotiques. Nouveaux antibiotiques antistaphylococciques. |
PMID | 11155724
(Publication Type: English Abstract, Journal Article, Review)
|
Chemical References |
- Anti-Infective Agents
- Carbapenems
- Cephalosporins
- Fluoroquinolones
- Virginiamycin
- quinupristin-dalfopristin
|
Topics |
- Anti-Infective Agents
(therapeutic use)
- Carbapenems
(therapeutic use)
- Cephalosporins
(therapeutic use)
- Drug Therapy, Combination
(therapeutic use)
- Endocarditis, Bacterial
(drug therapy, microbiology)
- Fluoroquinolones
- Humans
- Methicillin Resistance
- Staphylococcal Infections
(drug therapy, microbiology)
- Virginiamycin
(therapeutic use)
|